Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX Laboratories elects Karen Peacock to board, effective October 6, 2025

Neutral Impact 2 of 5 leadership Written later

IDEXX Laboratories added Karen Peacock, former CEO of Intercom, as an independent Class I director effective October 6, 2025, and expanded its board from ten to eleven members. The filing describes her compensation and committee roles but reports no financial results or changes in company guidance.

Key points

  • Karen Peacock elected independent Class I director effective October 6, 2025; board increased from ten to eleven members
  • Peacock appointed to the Compensation and Talent Committee and Finance Committee
  • Her annual director equity grants will be made December 1, 2025, prorated from October 6, 2025 to the 2026 annual meeting
  • Expected to stand for stockholder election as a Class I director at the 2027 annual meeting

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECOct 7, 2025, 7:06 AM ET
Accession number0001104659-25-097319

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.